COMy 2021 | Treatment options for relapsed young myeloma
Muzaffar Qazilbash, MD, University of Texas MD Anderson Cancer Center, Houston, TX, outlines the treatment options for young patients with multiple myeloma who relapse. For the transplant-ineligible population, a number of triplet regimens are recommended. These include DRd (daratumumab, lenalidomide, dexamethasone), KRd (carfilzomib, lenalidomide, dexamethasone), ERd (elotuzumab, lenalidomide, dexamethasone), and IRd (ixazomib, lenalidomide, dexamethasone). A second autologous stem cell transplant will be offered to patients who had a long first remission and are still considered transplant-eligible. This interview took place during the 7th World Congress on Controversies in Multiple Myeloma (COMy), 2021.
Disclosures
Research Funding: Janssen, BioLine, Angiocrine, NexImmune
